e-Drug3D
699
cas 20537-88-6
CLASS
VARIOUS
RADIATION-PROTECTIVE AGENTS
PRODRUG
REDUCTION OF THE CUMULATIVE RENAL TOXICITY OF CISPLATIN AND FOR THE REDUCTION OF THE TOXIC EFFECTS OF RADIATION ON NORMAL ORAL TISSUES
INTESTINAL-TYPE ALKALINE PHOSPHATASE (IAP) IS A MAJOR ISOENZYME INVOLVED IN THE HYDROLYSIS OF AMIFOSTINE (PMID12577238)
ROUTE (list)
INJECTION
ATC code
V03AF05
PK parameters
VD 7 LITER
Cl 120 LITER / HOUR
t1/2 0.13 HOUR
Solubility
FREELY SOLUBLE IN WATER
TARGET ALKALINE PHOSPHATASE
Unknown
Formula:
C5H15N2O3PS
Calculated chemical properties:
MW 212.21
NB_atoms 12
XLogP -1.51
PSA 95.428
NB_HD 3
NB_HA 5
fsp3 1.00
Lipinski(0=no;1=yes) 1
NB_atoms 12
XLogP -1.51
PSA 95.428
NB_HD 3
NB_HA 5
fsp3 1.00
Lipinski(0=no;1=yes) 1
FDA
NDA 020221 (pdf not found) INN (AMIFOSTINE) ETHYOL (COSETTE) APPROVAL= AP YEAR= 1995 DISCONTINUED
NDA 077126 (pdf not found) INN (AMIFOSTINE) AMIFOSTINE (SUN PHARM) APPROVAL= AP YEAR= 2008 DISCONTINUED
NDA 204363 (pdf not found) INN (AMIFOSTINE) AMIFOSTINE (EUGIA PHARMA SPECLTS) APPROVAL= AP YEAR= 2017 DISCONTINUED
NDA 020221 (pdf not found) INN (AMIFOSTINE) ETHYOL (COSETTE) APPROVAL= AP YEAR= 1995 DISCONTINUED
NDA 077126 (pdf not found) INN (AMIFOSTINE) AMIFOSTINE (SUN PHARM) APPROVAL= AP YEAR= 2008 DISCONTINUED
NDA 204363 (pdf not found) INN (AMIFOSTINE) AMIFOSTINE (EUGIA PHARMA SPECLTS) APPROVAL= AP YEAR= 2017 DISCONTINUED